Latest PARP inhibitor Stories
NOVATO, Calif., July 14, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
Researchers at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.
BOULDER, Colo., June 2, 2011 /PRNewswire/ -- Clovis Oncology, Inc. announced today an agreement with Pfizer Inc.
A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation.
A novel therapy designed to attack tumors in patients with a genetic mutation in either BRCA1 or BRCA2, slowed tumor growth in 85 percent of advanced breast cancer patients treated in a small study.
The presence of the protein poly (ADP-ribose) polymerase (PARP) in tumors can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona tomorrow (Saturday 27 March).
WALTHAM, Mass., Feb.
Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports.
Breast cancer patients who have triple negative breast cancer, an aggressive form of the disease, that has spread to other parts of the body, are being asked to participate in a clinical study of a promising new treatment called PARP inhibitors.
NEW YORK, Dec.